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Abstract
Purpose Fatigue is a frequently reported symptom by patients
with advanced cancer, but hardly any prospective information
is available about fatigue while on treatment in the palliative
setting. In a previous cross-sectional study, we found several
factors contributing to fatigue in these patients. In this study,
we investigated the course of fatigue over time and if psycho-
social factors were associated with fatigue over time.
Methods Patients on cancer treatment for incurable solid tumors
were observed over 6 months. Patients filled in the Checklist
Individual Strength monthly to measure the course of fatigue.
Baseline questionnaires were used to measure disease accep-
tance, anxiety, depressive mood, fatigue catastrophizing,
sleeping problems, discrepancies in social support, and self-
reported physical activity for their relationwith fatigue over time.
Results At baseline 137 patients and after 6 months 89 patients
participated. The mean duration of participation was
4.9 months. At most time points, fatigue scores were signifi-
cantly higher in the group dropouts in comparison with the
group participating 6 months (completers). Overall fatigue
levels remained stable over time for themajority of participants.
In the completers, 42 % never experienced severe fatigue, 29 %
persisted being severely fatigued, and others had either an in-
creasing or decreasing level. Of the investigated factors, low
reported physical activity and non-acceptance of cancer were
associated significantly to fatigue.
Conclusion A substantial number of participants never expe-
rienced severe fatigue and fatigue levels remained stable over
time. For those who do experience severe fatigue, non-
acceptance of having incurable cancer and low self-reported
physical activity may be fatigue-perpetuating factors.
Keywords Advanced cancer . Fatigue . Quality of life .
Palliative phase . Cancer treatment
Introduction
The main aim of cancer treatment in patients with advanced
incurable cancer is prolonging patients’ life while ideally
maintaining patients’ quality of life. Patients with advanced
cancer described fatigue to be their most distressing symptom
limiting their quality of life [8, 28]. Although the knowledge
of prevalence of fatigue, its course, and related factors in can-
cer survivors is extensive [1, 10, 17], the literature in patients
with advanced cancer is scarce and prospective research in
patients on active palliative cancer treatment is even more
limited.
With the new treatment options nowadays, the palliative
phase for patients with advanced cancer can last for years
[20, 27] and has been compared with a chronic illness [40].
When we are able to prolong patients’ life for years in the
palliative phase, attention towards the occurrence of fatigue
in this disease trajectory is relevant. In patients with advanced
cancer, prevalence rates of fatigue of 33–90 % have been
reported [7, 36, 38, 41]. Some researchers have suggested that
fatigue will increase when a patient moves further in his pal-
liative trajectory, in particular when being on active treatment
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[5, 7, 34]. Regrettably, most studies in patients within the
palliative trajectory have studied pooled data of patients at
different phases of their disease trajectory up to the final ter-
minal phase [5, 7, 34]. Also, the majority of studies that report
on fatigue in patients receiving palliative chemotherapy had
not been designed to investigate fatigue as a primary research
question. Some studies investigated fatigue in patients with
advanced cancer when admitted to a palliative care unit or
hospital for serious health deterioration [12, 18, 29, 36, 37].
These patients were mostly at a late palliative stage or terminal
phase and did not receive anticancer treatment. In an observa-
tional study aimed at fatigue during anticancer therapy in 99
patients with different stages of disease, fatigue levels
remained stable over 2 months [6]. We reported in a cross-
sectional study severe fatigue in 47 % palliative patients on
anticancer treatment, with higher fatigue scores in patients
who were receiving further lines of treatment [31]. A longitu-
dinal study is needed to determine whether fatigue increases
during palliative cancer treatment.
In cancer survivors, a model was developed to ex-
plain persistent severe fatigue obviously not associated
to somatic factors [35], and in addition, a successful
therapy based on this model was developed [15, 16].
In the abovementioned cross-sectional study in patients
with advanced cancer, we found several non-somatic
factors associated to fatigue similar to those in cancer
survivors [32]. The psychosocial factors such as non-
acceptance of having incurable cancer, anxiety, depres-
sive mood, fatigue catastrophizing cognitions towards
fatigue, sleeping problems, discrepancy in (expected
and experienced) social support, and low perceived
physical activity were all associated to fatigue. In the
current longitudinal study, we wanted to investigate
these factors prospectively for their contribution to fa-
tigue over time in patients with incurable cancer, while
on treatment. Our hypothesis was that the same psycho-
social factors are associated with fatigue over time and
contribute to fatigue over time independently.
Exploring the factors related to the course of fatigue pro-
spectively might bring us a step forward to the development of
a treatment model, on which interventions for fatigue can be
developed also in the palliative phase of cancer treatment.
Patients and methods
Between December 2008 and June 2010, patients on or about
to start with treatment for advanced, incurable cancer from the
departments of medical oncology of a university and a region-
al hospital in the southeastern part of the Netherlands were
asked to participate in this study. Physicians preselected po-
tentially eligible patients based on the following inclusion
criteria: diagnosis of advanced, incurable cancer; able to
receive palliative (symptom reducing and/or life prolonging)
cancer treatment; and able to fill in and return questionnaires
in Dutch. The main investigator (MP) approached potential
participants by telephone. She informed them about the study
and additional written information was sent to those who were
interested in the study.
Participants from the university medical center had the op-
portunity to either complete the baseline questionnaires using
a computer at the outpatient clinic (in combination with a
regular visit to the clinic) or fill in a paper-and-pencil version
at home. Patients from the regional hospital all received the
paper-and-pencil version at home. After the baseline investi-
gation, the fatigue questionnaire Checklist Individual Strength
was sent every month for 6 months. Six months after inclu-
sion, a final set of follow-up questionnaires was sent. A max-
imum of two telephone calls were made by the investigator to
complete the baseline and follow-up data. For the monthly
sent out fatigue questionnaires, no additional attempts were
made to complete these. Permission to conduct the study was
obtained from both institutional review boards of the partici-
pating hospitals, although this study did not fall under the
Medical Research Involving Human Subjects Act. All partic-
ipants provided verbal consent.
Instruments
General information on demographical characteristics, stage
and type of cancer, and current treatment was obtained from a
general questionnaire, eventually supplemented with data
from medical records. Fatigue severity was assessed with the
subscale fatigue of the Checklist Individual Strength (CIS).
This subscale consists of eight items asking for fatigue sever-
ity over the last 2 weeks; each item is scored on a 7-point
Likert scale; range is from 8 to 56; higher scores indicate more
severe fatigue. The validated cut-off score of 35 or higher was
used to determine severe fatigue [42, 43]. This score of 35 is
about two times the standard deviation (sd) above the mean
score of healthy controls. The subscale physical activity,
consisting of three items on a 7-point Likert scale, was used
to measure self-reported physical activity. Higher scores are
indicative for lower self-reported physical activity [3, 9]. The
CIS is a well-validated instrument with excellent psychomet-
ric properties [3, 9, 43].
Inappropriate coping with disease was measured with the
subscale Acceptance of the Illness Cognition Questionnaire
(ICQ) for chronic diseases. This subscale measures the degree
of acceptance of having cancer and consists of six items on a
4-point scale from 1 (do not agree) to 4 (completely agree)
[14]. It has shown good reliability with Cronbach’s alpha co-
efficients ranging from 0.84 to 0.91 in patients with chronic
diseases [13].
Anxiety was measured with the subscale anxiety of the
Hospital Anxiety and Depression Scale (HADS) [19, 24,
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45]. To assess depressive mood, the subscale depression of the
HADS was used [19, 24]. Both subscales consist of seven
items on a 4-point Likert scale. The HADS is an extensively
used and validated instrument [44].
Fatigue catastrophizing was measured by the Fatigue
Catastrophizing Scale (FCS), consisting of 10 items on a 5-
point scale from 1 (never true) to 5 (all of the time true) [4, 21].
Higher scores are indicative for more fatigue catastrophizing.
A total score is derived by computing the mean of 10 ratings.
This subscale has a good reliability with a Cronbach’s alpha of
0.85 [21].
Sleeping problems were measured by the sleep subscale of
the Symptom Checklist (SCL-90) [2], consisting of three
items on a 5-point scale from 1 (not at all) to 5 (very much).
Higher scores indicate lower quality of sleep. Patients were
asked if they, during the last month, (a) slept well, (b) had
difficulty with falling asleep, and (c) woke up early in the
morning. This subscale has a good reliability with a
Cronbach’s alpha of 0.73 [2].
Discrepancy between the received and desired amount of
social support was measured by the van Sonderen Social Sup-
port List-Discrepancies (SSL-D) [33], consisting of eight
items on a 4-point scale. Scores for the SSL-D range from 8
to 32. Higher scores are indicative for a higher discrepancy.
This instrument has a good reliability with a Cronbach’s alpha
of 0.95 [11].
Statistical methods
Descriptive statistics and frequencies were generated to
determine the sample characteristics and the course of fa-
tigue. To give insight into the course of fatigue, we also
differentiated between a group who dropped out (group
DO) and a group that still participated at 6 months (com-
pleters). The non-parametric Mann-Whitney test was used
to investigate differences in fatigue scores between the
groups DO and completers. A linear regression analysis
(enter method) was performed to assess the relationship
200 patients were approached 
162 patients agreed to participate  
38 refused to participate  
Baseline T0: 137 patients returned the 
questionnaires  
At 1 month: T1: returned n = 116 (CIS) 
At 2 months: T2: returned n = 119 (CIS) 
AT 3 months: T3: returned n = 108 (CIS) 
At 4 months: T4: returned n = 103 (CIS) 
At 5 months: T5: returned n = 103 (CIS) 
At 6 months T6: returned n = 89 (CIS & Follow-up 
questionnaires) 
25 did not return the questionnaires  
Questionnaire sent n =137 
Questionnaires sent n = 106 
Questionnaire sent n = 132 
Questionnaire sent n = 127 
Questionnaire sent n = 121 
Questionnaire sent n = 115 
Fig. 1 Flowchart of the number
of participants at the different
time points
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of psychosocial factors at baseline to fatigue over time.
SPSS software (version 20) was used to analyze our data
(SPSS Inc., Chicago, IL, USA).
Results
Two hundred patients with advanced cancer receiving treat-
ment were approached for this study. One hundred and sixty-
two patients agreed to participate and 137 of them (69 %)
filled in the baseline questionnaires. Non-participants
(n = 63) did not differ from the participants with regard to
sex, age, and cancer diagnosis as has been reported elsewhere
[31]. Figure 1 shows the number of participants at the different
time points. The mean duration of follow-up for all partici-
pants (AP) in the study, including dropouts, was 4.9 months.
During the study period of 6 months, 89 patients participated
during all 6 months (completers), the remaining 48 patients
were considered as the group DO and they participated for a
mean period of 2.7 months (range 1–5 months). Twelve of
them only filled in the baseline measurements. Reasons for
dropout were as follows: no longer being able to fill in ques-
tionnaires (n = 7), died during the study (n = 20), and not
wanting to participate anymore (n = 4). Seventeen patients
gave no reason for dropout. Demographic and cancer- and
treatment-related characteristics of all participants at baseline
are shown in Table 1. We found no significant differences
between the groups DO and completers on gender, age, type
of cancer, treatment modalities, and treatment line (not
shown).
The mean fatigue scores and percentages of severely fa-
tigued patients at the different time points of AP, of the group
DO, and the group completers are shown in Table 2. Themean
fatigue scores in all three groups remained stable over time. At
time points T1, T2, T3, and T4, the mean fatigue scores of the
group DO were significantly higher in comparison with the
completers. Also, the severely fatigued percentage remained
quite stable over time within the group AP. The group DO
showed an increase in percentages of severely fatigued pa-
tients during the first 2 months, and the completers showed
the opposite. After the third month, the percentage of severely
fatigued stabilized in both subgroups.






















Baseline/T0 32 (13.2) 47 (64/136) 35 (13.1) 54 (26/48) 31 (13.1) 43 (38/89) 0.187
T1 32 (12.9) 46 (53/116) 38 (11.7) 67 (20/30) 30 (12.8) 38 (33/86) 0.007
T2 32 (12.8) 40 (48/119) 38 (12.9) 59 (19/32) 29 (11.9) 33 (29/87) 0.001
T3 32 (13.8) 45 (49/108) 38 (14.2) 57 (12/21) 31 (13.4) 43 (37/84) 0.045
T4 31 (13.9) 44 (45/103) 39 (13.6) 58 (11/19) 30 (13.1) 41 (34/84) 0.017
T5 31 (13.8) 44 (45/103) 38 (13.0) 50 (7/14) 31 (13.4) 43 (38/89) 0.082
T6 32 (13.9) 44 (39/89) 32 (13.9) 44 (39/89)
Table 1 Baseline demographic and cancer- and treatment-related
characteristics
Characteristics Participants, n (%)
Participants 137
Female gender 84 (61)
Male gender 53 (39)
Mean age, years (range) 59 (30–79)
Marital status
Married 111 (81)










Oral-targeted therapy 21 (15)
Hormonal therapy 20 (15)
Chemo-targeted therapy 19 (14)
Radiotherapy 2 (1)
Chemoradiotherapy 1 (1)






a Two patients were about to start with their first-line treatment
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In the completers, 42 % (37/89) never experienced severe
fatigue and 29% (26/89) experienced severe fatigue at all time
points. Thirteen patients became severely fatigued (15 %) and
in 12 patients (14 %) it decreased in the 6-month follow-up,
from severely to not severely fatigued. The linear regression
analysis within the completers showed that 51 % of the vari-
ance on fatigue severity may be explained by the psychosocial
factors, of which the factors non-acceptance of having incur-
able cancer and self-reported physical activity contributed sig-
nificantly to the severity of fatigue over the 6-month period
(see Table 3).
Also the scores of the investigated psychosocial variables
remained quite stable over time (see Table 4).
Discussion
In this study, we investigated the course of fatigue over a
period of 6 months in patients with advanced cancer receiving
palliative cancer treatment. Additionally, we prospectively ex-
plored which psychosocial factors contributed to the severity
of fatigue over this period. To our knowledge, this is the first
study in which the severity of fatigue is longitudinally
observed in cancer patients on active treatment in the pallia-
tive phase.
Of the patients who were able to participate during the total
period of 6 months, 42 % were not severely fatigued and did
not become so during this period. About a quarter of these
patients was severely fatigued and remained so. In 15 %, a
decrease from severe fatigue to non-severe fatigue occurred,
and in 12 % of patients, fatigue level increased from non-
severe to severe fatigue. Interestingly, in two thirds of the
patients, the fatigue level did not change during the course
of the study and the mean score was rather stable for the whole
group participants during the 6-month study period. However,
patients who dropped out somewhere during the study often
had a significantly higher fatigue level at the various time
points compared to the patients who remained in the study.
Although fatigue is the most often reported symptom in
patients with incurable cancer [5, 36, 37], we demonstrated
for the first time that not every patient suffers from severe
fatigue. In the group of patients who remained in the study,
the percentage of severely fatigued patients was lower com-
pared with patients who dropped out. This might suggest that
the patients who still participated after 6 months are part of a
relatively fit group. This suggestion is supported by the find-
ing of higher fatigue scores at baseline in the group who
Table 4 Baseline and follow-up
values of investigated psychoso-
cial factors
Variables Baseline Follow-up
N Median Interquartile range N Median Interquartile range
Acceptance 137 17 6 85 18 6
Catastrophizing 133 16 7 86 18 9
Depressive mood 134 4 4 87 4 5
Anxiety 134 5 6 87 4 7
Sleep quality 124 6 4 78 5 4
Discrepancies social support 136 8 1 84 8 1
Self-reported physical activity 137 12 9 82 11 11
Table 3 Linear regression to
predict fatigue severity over
the 6-month follow-up
Independent variables at baseline Beta Dependent variable: mean CIS fatigue of all follow-up
assessments
95 % CI for B P value
Lower bound Upper bound
Acceptance (n = 89) −0.263 −1.366 −0.045 0.037
Catastrophizing (n = 87) 0.049 −0.322 0.474 0.704
Depressive mood (n = 86) 0.204 −0.169 1.635 0.110
Anxiety (n = 86) −0.672 −0.998 0.495 0.504
Sleep quality (n = 79) −0.009 −0.870 0.800 0.933
Discrepancies social support (n = 89) −0.079 −1.702 0.739 0.434
Self-reported physical activity (n = 88) 0.504 0.580 1.406 0.000
R2 = 0.514
Support Care Cancer (2016) 24:1349–1355 1353
dropped out and by the finding that the main reason for drop-
out was deterioration of the health status or death. Moreover,
the percentage of patients that changed levels of fatigue sever-
ity in the group that continued follow-up was rather low
(29 %), suggesting that several factors perpetuate the fatigue
during this observation period of 6 months. A study that
would include all patients at the same time within their disease
trajectory, i.e., at primary diagnosis of incurable cancer, and
that will follow the patients longitudinally from that time on-
wards might provide more insight into the course of fatigue
and associated symptoms.
Two of the investigated fatigue-associating factors were
related to the course of fatigue (the mean fatigue score during
the follow-up period), namely, a low level of self-reported
physical activity and difficulties in acceptance of having in-
curable cancer. This implicates that influencing and address-
ing these factors might reduce fatigue and may have an im-
provement on the quality of life in these patients. Few studies
already addressed the issue of physical activity and focused on
exercise training to tackle fatigue but did not reach clinically
relevant reductions in fatigue [30]. Other studies had small
samples and mainly investigated the feasibility of exercise
programs in patients in the palliative phase [22, 25, 26]. It is
important to remark that in our study, we did not measure
actual physical activity, for example by actimetry, but assessed
the self-reported level of physical activity.
To reflect on the difficulties of acceptance of having incur-
able cancer relating to fatigue, we only found in literature that
acceptance of having incurable cancer can be a specific factor
for palliative patients. It has been described as a psychological
process that evolves throughout the course of a disease trajec-
tory [39]. To our awareness, however, this is the first study that
found a relation with problems of acceptance with having
incurable cancer and fatigue.
For five other postulated perpetuating factors, we could not
show a relation with the course of fatigue in the palliative
phase. There might be two reasons why we did not find such
a relation. First, it could be explained by individual differences
in relevance of these factors, an observation which has also
been made in fatigue in cancer survivors [15, 32]. Second, it
could be that we investigated the wrong factors. This would
mean that factors other than postulated in our study may con-
tribute to the course of fatigue. It is, however, difficult to state
which factors we could have missed because literature on this
topic is very scarce.
There are several limitations to be acknowledged. Al-
though all participants had advanced cancer at baseline, the
patients were not at the same point in their disease trajectory.
At baseline, two patients were just about to start with their
first-line treatment, while all other participants were some-
where within their disease trajectory varying from the first to
the fourth treatment line. Regrettably, we have no information
whether patients still received treatment at 6 months follow-up
and if so, the kind of treatment or treatment line they were
receiving at the final assessment, nor the effect on oncologic
parameters. In line with this, we have no information on the
median survival time of the participants.
Another limitation might be the questionnaires we used.
We used the subscale anxiety of the HADS as a proxy for
heightened fear of disease progression.We wanted to get more
insight into fear related to having an incurable disease. At the
time of study, such a validated questionnaire was not available
in Dutch. Recently, such a questionnaire, the Bfear of progres-
sion questionnaire,^ has been validated and this one could
have been more suitable [23].
To summarize, an important conclusion from this study is
that not all patients who continue active treatment within the
palliative trajectory suffer from severe fatigue and only a mi-
nority change fatigue level over time. For those who do expe-
rience severe fatigue, non-acceptance of having incurable can-
cer and low perceived physical activity seem to be fatigue-
perpetuating factors. Fatigue interventions might therefore be
directed at helping palliative patients to accept the cancer and
improving their level of (subjective) physical activity.
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